Lineage Cell Therapeutics (LCTX) Liabilities and Shareholders Equity (2010 - 2026)

Lineage Cell Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $109.5 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 1.99% year-over-year to $109.5 million in Q1 2026; TTM through Mar 2026 was $402.6 million, a 5.14% decrease from a year earlier, with the FY2025 full-year figure at $112.6 million, down 0.56% from the prior year.
• Liabilities and Shareholders Equity slipped to $109.5 million in Q1 2026 per LCTX's latest filing, from $112.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $144.5 million in Q1 2022 and bottomed at $89.6 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $111.7 million (2023), against an average of $111.9 million.
• Biggest YoY gain for Liabilities and Shareholders Equity was 12.97% in 2022; the steepest drop was 29.15% in 2022.
• Year by year, Liabilities and Shareholders Equity stood at $123.7 million in 2022, then decreased by 18.31% to $101.0 million in 2023, then grew by 12.08% to $113.2 million in 2024, then retreated by 0.56% to $112.6 million in 2025, then decreased by 2.71% to $109.5 million in 2026.
• Per Business Quant, the three latest LCTX Liabilities and Shareholders Equity figures stand at $109.5 million (Q1 2026), $112.6 million (Q4 2025), and $89.6 million (Q3 2025).